USFDA Approves Biocon’s Cancer Drug Jobevne™

Biocon Limited has announced that its subsidiary, Biocon Biologics, has received approval from the U.S. Food and Drug Administration (USFDA) for Jobevne™ (bevacizumab-nwgd), a biosimilar version of Avastin® (bevacizumab).  

This monoclonal antibody is used in treating multiple forms of cancer and works by inhibiting angiogenesis, the formation of new blood vessels, thus restricting the tumor’s blood supply and growth. 

Strengthens Oncology Portfolio in the U.S. 

The approval of Jobevne™ marks a significant expansion of Biocon Biologics’ biosimilar oncology offerings in the United States, which already include OGIVRI (Trastuzumab-dkst) and FULPHILA (Pegfilgrastim-jmdb). This addition reinforces the company’s commitment to providing affordable biologics globally. 

Global Presence and Market Opportunity 

Biocon Biologics already markets Bevacizumab in Europe and Canada under the brand name ABEVMY, approved in 2021. The U.S. market presents a major opportunity, with sales of bevacizumab reaching ~$2 billion in 2023. 

Also Read: Cipla Gets USFDA Approval for Cancer Drug Paclitaxel.

Pioneering Leadership in Biosimilars 

Biocon Biologics is recognised for achieving multiple industry milestones, such as the first U.S. approvals for OGIVRI, FULPHILA, and the interchangeable biosimilar SEMGLEE (insulin glargine). The company currently serves over 5 million patients annually and maintains a strong development pipeline with 20 biosimilar assets, including monoclonal antibodies and insulins. 

The CEO and Managing Director of Biocon Biologics Ltd, Shreehas Tambe, said, “The U.S. FDA approval of JOBEVNE™ (bevacizumab-nwgd) is a significant milestone—our seventh biosimilar approved in the U.S. and a strong addition to our robust oncology portfolio. It underscores the depth of our scientific expertise and commitment to expanding access to high-quality, affordable biologics. We look forward to working with all stakeholders to bring more treatment options to patients.” 

Biocon Share Price Performance 

On April 11, 2025, Biocon share price opened at ₹320.00, up from its previous close of ₹306.30. At 10:07 AM, the share price of Biocon was trading at ₹315.65, up by 3.05% on the NSE. 

Conclusion 

The USFDA approval of Jobevne™ underscores Biocon Biologics’ leadership in biosimilars and reinforces its strategic position in the oncology space, strengthening access to affordable cancer therapies in the U.S. market. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.